Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Recursion Pharmaceuticals ( (RXRX) ) is now available.
On March 25, 2026, Recursion Pharmaceuticals announced that seasoned oncology drug developer Vicki Goodman, M.D., will become Chief Medical Officer effective April 6, 2026, as current CMO David Mauro, M.D., Ph.D., transitions out of the role but remains an advisor until May 29, 2026. The move brings to Recursion a leader with extensive experience across biotech, large pharma, and the U.S. Food and Drug Administration, including senior roles tied to marquee oncology drugs such as KEYTRUDA, OPDIVO, YERVOY, and dabrafenib.
The appointment comes as Recursion advances its AI-driven pipeline toward key clinical and regulatory milestones, with management emphasizing Goodman’s track record in late-stage development, regulatory affairs, and building development organizations to support disciplined, data-driven decisions. The leadership change underscores Recursion’s efforts to strengthen its medical and clinical operations at a pivotal stage, while the company credits Mauro with bolstering its clinical organization and progressing assets like REC-4881 during his approximately three-year tenure as CMO.
The most recent analyst rating on (RXRX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
The score is held back primarily by weak financial performance (large losses and heavy cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting these, the latest earnings call was constructive with extended runway, cost discipline, and partner validation, which supports a mid-range overall score despite execution and milestone-dependence risks.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company that uses an AI-native, end-to-end drug discovery and development platform, the Recursion OS, to decode biology and develop differentiated investigational medicines. The company focuses on oncology, rare disease, neuroscience, immunology, and other high-need therapeutic areas, operating automated biology and chemistry laboratories in Salt Lake City and Milton Park with additional offices in New York, Montréal, and London.
Recursion’s platform integrates proprietary multimodal data, purpose-built AI models, and teams fluent in both science and AI to translate complex biology into potential therapies at scale. Its business model combines wholly owned and partnered pipelines across multiple therapeutic domains, positioning the company at the intersection of technology and drug development in competitive global biopharma hubs.
Average Trading Volume: 19,216,363
Technical Sentiment Signal: Sell
Current Market Cap: $1.71B
See more data about RXRX stock on TipRanks’ Stock Analysis page.